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Individuals with autism experience difficulty with social interaction and communication. Effective treatments
for these individuals are sorely lacking, especially when it comes to medication. Most currently available
drugs target symptoms such as aggression and irritability that occur alongside the primary symptoms of the
disorder. These individuals also commonly experience anxiety and heightened stress responses. In the
present dissertation, the body's stress system was explored as a potential target for medication for
individuals with autism. A drug called propranolol that dampens anxiety and stress was examined for its
effects on social and cognitive behavior in adults and adolescents with autism. Improvements associated
with propranolol were seen for both social and cognitive functioning. Additionally, measurements of stress
and anxiety were able to predict which individuals responded to the drug. These findings suggest that
propranolol may be an effective medication for some individuals with autism, but further work in the form of
large-scale clinical trials is necessary. Through these future studies, this line of work may eventually help
improve the lives of individuals on the autism spectrum.
